What your existing tests already answer
Before any new assessment, it helps to separate two questions. The first is: what does the record already establish? A prostate biopsy report with Gleason grade and number of positive cores, a PSA history, and any imaging you have had usually tell a clinician what type of cancer is present and how aggressive it appears. These are the facts that do not change simply because you travel.
The second question is what those records cannot answer. A pathology report from another laboratory may be readable but not necessarily accepted as the final basis for surgery. Imaging performed months ago may not reflect the current stage. A PSA value without a trend line is less informative than a series. And no record tells the treating team how you currently urinate, whether you have bothersome symptoms, or what you consider an acceptable trade-off between cancer control and side effects.
So the practical starting point is not to repeat everything. It is to assemble a clear summary of what is already known, then identify the specific gaps that a new assessment would fill. That distinction matters because it determines what you send first, what may need to be repeated in China, and what questions you should ask before agreeing to any test.
What a new assessment adds: staging, risk and surgical fit
A new assessment for robotic prostatectomy is not a repeat of your diagnosis. It is a clinical judgement about whether surgery is appropriate for you now, and if so, what operation and what aftercare. Radical prostatectomy removes the prostate for selected prostate cancers, and robotic instruments are controlled by the surgeon. That description tells you what the operation is, but not whether it is right for your situation.
The treating team will want to review the cancer control picture: the grade, the stage, whether the disease appears confined to the prostate, and whether there is any evidence it has spread. They will also want to understand your functional priorities. Urinary continence and erectile function before surgery are relevant to how you weigh risks and what support you may need afterwards. These are not abstract concerns; they shape the conversation about whether to operate, when, and with what technique.
A new assessment may also include a pathology review. If your biopsy was done elsewhere, the receiving hospital may ask its own pathologist to re-read the slides or blocks. This is not a comment on the quality of your original report. It is a way for the operating team to work from a diagnosis they have verified themselves. Ask whether a pathology review is required, what material they need, and how long it takes to arrange.
Imaging is another area where new assessment may differ from old records. If you have had an MRI or a PSMA PET scan, the team will want to know when it was done and whether the images are available in a format they can review. They may decide that existing imaging is sufficient, or they may recommend additional staging. That decision belongs to the treating clinicians, and it depends on your individual findings, not on a standard checklist.
Cancer control and functional priorities: questions to ask
The most useful preparation you can do before a robotic prostatectomy assessment is to clarify your own priorities and then ask the team how they would address them. Cancer control is the first priority for most patients, but what that means in practice depends on the stage and grade. Ask how the proposed operation addresses the cancer, what the pathology after surgery will show, and what follow-up will be needed.
Functional outcomes deserve the same direct conversation. Ask about urinary continence: what the team's approach is to nerve-sparing, what catheter care will involve, and what support is available if continence is slow to return. Ask about erectile function: whether nerve-sparing is possible in your case, what the realistic range of outcomes is, and what options exist if function does not recover as hoped. These are not guarantees; they are the questions that help you understand the trade-offs.
It is also reasonable to ask how the team handles the uncertainty. If the final pathology shows a more extensive cancer than expected, what would that mean for follow-up or additional treatment? If the margins are positive, what surveillance or treatment would be discussed? You are not asking for a prediction; you are asking how the team plans to support you through the range of possible outcomes.
Write these questions down before the appointment. In a cross-language consultation, it is easy to lose track. A written list, translated if needed, helps you cover the points that matter most to you.
Catheter care, recovery support and follow-up planning
Robotic prostatectomy involves a catheter after surgery, and the details of catheter care, removal timing and discharge instructions are set by the treating team. Do not rely on general timelines from other countries or other hospitals. Ask the team in China what their protocol is, who will teach you catheter care, what warning signs require urgent contact, and how follow-up is arranged after you leave the hospital.
Recovery support is not only about the operation. It includes pain management, wound care, activity guidance, and pelvic floor exercises if recommended. Ask whether the hospital provides written instructions in English, whether a physiotherapist or continence nurse is involved, and how you can reach the team if you have questions after discharge. If you are travelling from overseas, ask how follow-up can be coordinated with your doctors at home.
Pathology review after surgery is another point to clarify. The final pathology report guides further decisions, and you will want to know when it will be available, how it will be explained to you, and whether a copy can be provided for your records. Ask whether the report will be in English or whether an interpretation is arranged.
These are administrative and clinical questions, and the answers vary by hospital. The point is not to assume a standard process, but to ask the specific hospital what its process is.
What the hospital decides, and what you decide
It is important to be clear about the division of responsibility. The hospital and its licensed clinicians decide whether robotic prostatectomy is suitable for you, what tests are needed, and what the treatment plan will be. ChinaSpecialistCare provides information and non-clinical coordination; we do not diagnose, prescribe, or decide suitability. An initial enquiry does not require buying a proxy consultation, and a proxy consultation is optional, not a prerequisite for every appointment.
What you decide is whether to pursue an assessment in China at all, what records to share, and what questions to ask. You can start with a brief summary by the enquiry form, email or WhatsApp. After first contact, we can explain how to share records. Do not send passport numbers, card details or a complete medical archive in the initial enquiry.
If you are considering robotic prostatectomy in China, the related CSC reference page describes the procedure and the planning context. Use it alongside this guide, not as a substitute for a clinical assessment.
The practical next step is to gather your existing records: biopsy report, PSA history, imaging reports and any recent clinic letters. Then ask the hospital, through a coordinated enquiry, what they would need to review and what a new assessment would add in your case. That is a records-based question, and it can be answered before you travel.
Sources & scope of this guide
References and official service information relevant to this guide.
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.